Specialist in preclinical proof-of-concept and efficacy studies

Motac Neuroscience, with operations in Bordeaux (France) and Beijing (China), is a CRO specialized in preclinical research for neurological and neurodegenerative disorders. Motac Neuroscience supports biotechnology and pharmaceutical companies by generating robust and translationally relevant preclinical data to advance therapeutic candidates toward clinical development.

Motac Neuroscience provides integrated platforms combining rodent and non-human primate models with behavioral assessments, in vivo imaging, biomarker analysis and histopathological endpoints. These multidisciplinary approaches generate comprehensive datasets that support critical decision-making from proof-of-concept to IND-enabling studies.

Motac Neuroscience has expert experience in neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis, as well as other neurological conditions including spinal cord injury, cognitive impairment and sleep–wake disorders. The company designs and conducts customized studies aimed at reducing development risk and supporting the translation of innovative therapies targeting central nervous system disorders.